The current year looks to be ‘shaping up nicely' for GSK PLC (LSE:GSK, NYSE:GSK), according to Barclays Capital in the wake of Wednesday’s fourth-quarter and full-year results.
It did, however, say it is trimming down forecast sales for HIV products going forward to incorporate 'stocking impacts'.
Counterbalancing this is an increase in the sales target for GSK’s new drug for RSV, a cold-like illness.
Repeating its ‘equal weight’ recommendation, Barclays said it still had concerns over the drugs giant’s pipeline of prospective products.
The bank repeated its £14.50 a share price target, representing a modest premium to the current £14.21 the stock is currently changing hands for.
Of the 23 banks and brokers logged as following GSK, 11 are fence-sitters and eight are ‘buyers’.